Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
about
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
description
clinical trial
@en
klinisch onderzoek
@nl
name
Setmelanotide (RM-493), Melano ...... ith Moderate to Severe Obesity
@en
type
label
Setmelanotide (RM-493), Melano ...... ith Moderate to Severe Obesity
@en
prefLabel
Setmelanotide (RM-493), Melano ...... ith Moderate to Severe Obesity
@en
P1050
P1476
A Phase 3 Trial of Setmelanoti ...... ith Moderate to Severe Obesity
@en
P3098
NCT03746522
P580
2018-12-10T00:00:00Z
P582
2020-06-30T00:00:00Z